A genetically-engineering bone marrow stem cell therapy for stroke

引言：我们已经报道了骨髓细胞移植在脑缺血动物模型中的治疗效果。在本研究中，我们将基因工程骨髓干细胞移植到大脑中动脉闭塞模型大鼠中，以研究其潜在的治疗效果。我们制备了五种基因工程骨髓干细胞，1）用hTERT基因使干细胞永生化，2）用BDNF基因促进神经营养作用，3）用GDNF基因促进神经营养作用，（4）Ang-1基因促进血管生成;（5）P1 GF基因促进血管生成。病变大小进行了评估，使用磁共振成像和光谱，和组织学methods.Results：基因工程骨髓干细胞移植减少病变体积。病灶大小的减少可以在体内与MRI进行评估，并与随后的组织学检查的brain.Conclusion：这项工作表明，高纯度的基因工程骨髓干细胞是神经保护和angeigenetic在脑缺血模型。因此，骨髓的高度纯化、扩增和基因工程细胞组分已证明在脑缺血中的治疗益处。

Introduction : We have reported that transplantation of bone marrow cells has demonstrated therapeutic efficacy in animal models of cerebral ischemia. In the present study, we transplanted genetically-engineering bone marrow stem cells into middle cerebral artery occlusion model rats to study their potential therapeutic benefit.Methdos : We have made five genetically-engineering bone marrow stem cells, 1) to immortalize the stem cells with hTERT gene, 2) to promote the neurotrophic effects with BDNF gene, 3) to promote the neurotrophic effects with GDNF gene, 4) to promote the angiogenetic effects with Ang-1 gene, 5) to promote the angiogenetic effects with P1GF gene. Lesion size was assessed using MR imaging and spectroscopy, and histological methods.Results : Transplantation of genetically-engineering bone marrow stem cells reduced lesion volume. The reduction of lesion size could be assessed in vivo with MRI and was correlated with subsequent histological examination of the brain.Conclusion : This work demonstrates that highly purified genetically-engineering bone marrow stem cells are neuroprotective and angeigenetic in cerebral ischemia models. Thus, a highly purified, expanded, and genetically-engineered cellular component of bone marrow has demonstrated the therapeutic benefits in cerebral ischemia.